Dermata Therapeutics, Inc. (DRMA): Price and Financial Metrics

Dermata Therapeutics, Inc. (DRMA): $0.35

0.01 (+3.19%)

POWR Rating

Component Grades








Add DRMA to Watchlist
Sign Up

Industry: Biotech




#201 of 370

in industry

DRMA Price/Volume Stats

Current price $0.35 52-week high $3.68
Prev. close $0.34 52-week low $0.23
Day low $0.32 Volume 25,570
Day high $0.35 Avg. volume 728,250
50-day MA $0.41 Dividend yield N/A
200-day MA $0.78 Market Cap 2.32M

DRMA Stock Price Chart Interactive Chart >

Dermata Therapeutics, Inc. (DRMA) Company Bio

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.

DRMA Latest News Stream

Event/Time News Detail
Loading, please wait...

DRMA Latest Social Stream

Loading social stream, please wait...

View Full DRMA Social Stream

Latest DRMA News From Around the Web

Below are the latest news stories about DERMATA THERAPEUTICS INC that investors may wish to consider to help them evaluate DRMA as an investment opportunity.

Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug

Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.

Yahoo | November 17, 2023

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today ...

Yahoo | November 16, 2023

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

- DMT310 Phase 3 STAR-1 (Spongilla Treatment of Acne Research) clinical trial will evaluate the efficacy and safety of once-weekly treatments of DMT310 for 12 weeks in moderate-to-severe acne patients -- Topline results from STAR-1 clinical trial ...

Yahoo | November 16, 2023

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 -- Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 -- Completed start-up activities to support DMT310 Phase 3 STAR-1 ...

Yahoo | November 9, 2023

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

- Dermata is prepared to initiate DMT310 Phase 3 STAR-1 clinical trial by the end of 2023 -- Investigational sites have been selected -- Clinical trial materials are ready to be shipped to investigational sites -SAN DIEGO, CA / ACCESSWIRE / October ...

Yahoo | October 26, 2023

Read More 'DRMA' Stories Here

DRMA Price Returns

1-mo -12.50%
3-mo -12.72%
6-mo -45.31%
1-year -87.76%
3-year N/A
5-year N/A
YTD -42.62%
2023 -90.68%
2022 -76.49%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!